MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

Search

Ipsen SA.

Închisă

SectorFinanțe

98.05 -0.31

Rezumat

Modificarea prețului

24h

Curent

Minim

96.1

Maxim

98.5

Indicatori cheie

By Trading Economics

Venit

-118M

114M

Vânzări

71M

1.8B

P/E

Medie Sector

21.241

20.525

Randament dividend

1.54

Marjă de profit

6.249

Angajați

5,358

EBITDA

228M

710M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+21.76% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

1.54%

4.36%

Statistici piață

By TradingEconomics

Capitalizare de piață

7.5B

Deschiderea anterioară

98.36

Închiderea anterioară

98.05

Scor tehnic

By Trading Central

Încredere

Very Strong Bullish Evidence

Ipsen SA. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

10 dec. 2024, 07:05 UTC

Market Talk

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Comparație

Modificare preț

Ipsen SA. Așteptări

Obiectiv de preț

By TipRanks

21.76% sus

Prognoză pe 12 luni

Medie 119.75 EUR  21.76%

Maxim 145 EUR

Minim 100 EUR

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIpsen SA. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

8 ratings

3

Cumpărare

4

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

94.4 / 99.15Suport & Rezistență

Termen scurt

Very Strong Bullish Evidence

Termen mediu

Very Strong Bearish Evidence

Termen lung

Strong Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.